Halosehat
Halosehat18
About
What does Halosehat do?
Hello Sehat offers a comprehensive platform for reliable health information, including articles, health tools like BMI and pregnancy calculators, and community forums for support. It aims to empower individuals to make informed health decisions and connect with others facing similar health journeys.
What is Halosehat's revenue?
StartupHub estimates Halosehat's annual revenue at $4.7M (range $2.9M to $8.1M, 65% confidence), based on comparable companies in the sector.
Where is Halosehat headquartered?
Halosehat is headquartered in Jakarta, Indonesia.
When was Halosehat founded?
Halosehat was founded in 2017.
What industry does Halosehat operate in?
Halosehat operates in HealthTech, MedTech, Digital Health, Medical Information, Health Content, Community Platform.
How many employees does Halosehat have?
Halosehat has approximately 35 people on record.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Recordatorios por WhatsApp para el paciente y tranquilidad para quien lo acompaña. Gratis, sin apps que descargar.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
An interoperable digital health network leveraging AI to enable data exchange and improve healthcare delivery.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 7 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.